IP Library Granted Patent US 8,198,429
Granted Patent B2
US 8,198,429 · App. 12/853,180 · Granted Jun 12, 2012

Antisense antiviral compounds and methods for treating a filovirus infection

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,198,429
App. No.
12/853,180
Granted
Jun 12, 2012
Kind
B2
Abstract

The present invention provides antisense antiviral compounds, compositions, and methods of their use and production, mainly for inhibiting the replication of viruses of the Filoviridae family, including Ebola and Marburg viruses. The compounds, compositions, and methods also relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds include phosphorodiamidate morpholino oligonucleotides (PMOplus) having a nuclease resistant backbone, about 15-40 nucleotide bases, at least two but typically no more than half piperazine-containing intersubunit linkages, and a targeting sequence that is targeted against the AUG start site region of Ebola virus VP35, Ebola virus VP24, Marburg virus VP24, or Marburg virus NP, including combinations and mixtures thereof.

Claims (6)

1. A composition, comprising a first and a second antisense oligonucleotide, wherein each oligonucleotide is composed of morpholino subunits linked by phosphorous-containing intersubunit linkages which join a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of an adjacent subunit in accordance with the structure:

wherein Y 1 ═O, Z═O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is —N(CH 3 ) 2 or 1-piperazino, wherein the first oligonucleotide is targeted against Marburg virus NP and consists of the sequence set forth in SEQ ID NO:79, and wherein the second oligonucleotide is targeted against Marburg virus VP24 and consists of the sequence set forth in SEQ ID NO:80.

2. The composition of claim 1 , comprising an approximately 1:1 mixture of equivalent concentrations (w/v) of the first and second antisense oligonucleotides.

3. A composition, comprising a first and a second antisense oligonucleotide, wherein each oligonucleotide is composed of morpholino subunits linked by phosphorous-containing intersubunit linkages which join a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of an adjacent subunit in accordance with the structure:

wherein Y 1 ═O, Z═O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is —N(CH 3 ) 2 or 1-piperazino, wherein the first oligonucleotide is targeted against Ebola virus VP24 consists of the sequence set forth in SEQ ID NO:77, and wherein the second oligonucleotide is targeted against Ebola virus VP35 and consists of the sequence set forth in SEQ ID NO:78.

4. The composition of claim 3 , comprising an approximately 1:1 mixture of equivalent concentrations (w/v) of the first and second antisense oligonucleotides.

Assignments (4)
SECURITY INTEREST Recorded May 7, 2025
From: SAREPTA THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 071218/0445 →
CHANGE OF NAME Recorded Feb 27, 2014
From: AVI BIOPHARMA, INC.
To: SAREPTA THERAPEUTICS, INC.
Reel/Frame 032366/0677 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY ADDRESS PREVIOUSLY RECORDED ON REEL 025773 FRAME 0486. ASSIGNOR(S) HEREBY CONFIRMS THE ADDRESS OF AVI BIOPHARMA INC. AS 4575 SOUTHWEST RESEARCH WAY, SUITE 200, CORVALLIS, OREGON 97333. Recorded Mar 10, 2011
From: IVERSEN, PATRICK L.; WELLER, DWIGHT D.
To: AVI BIOPHARMA, INC.
Reel/Frame 025922/0668 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2010
From: IVERSEN, PATRICK L.; WELLER, DWIGHT D.
To: AVI BIOPHARMA, INC.
Reel/Frame 025773/0486 →